Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead's Late-Stage R&D Misfire Gives Respite To Competing Myelofibrosis Therapies

Executive Summary

The JAK inhibitor momelotinib meets some endpoints but misses others in two late-stage clinical studies in myelofibrosis, a condition that has proved recalcitrant to various new approaches, leaving Incyte/Novartis’s marketed product ruxolitinib as one of the few successes.

Advertisement

Related Content

Misery In Myelofibrosis: Pacritinib Setback A Boost For Jakafi
Gilead Admits It Needs M&A To Resume Growth, But Stays Quiet
Gilead Plays Up Its Strength As Market Awaits Business Development Moves
Gilead Coming To The End Of HCV Road With Triple-Drug Regimen
Imetelstat Study Blip Beats Geron’s Shares Down
CTI BioPharma’s Pacritinib Meets One Co-Primary Endpoint, Just Misses Another, In PERSIST-2
Gilead JAKs up oncology presence with $510m YM buy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097695

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel